Transradial Selective Catheterization of the Celiac Artery in Obese Patients
25 de noviembre de 2019 actualizado por: Olivier F. Bertrand, Laval University
Transradial Selective Catheterization of the Celiac Artery in Obese Patients: A Pilot Study
BACKGROUND:
- Obesity, with its associated comorbidities, is set to become a major risk factor for cardiovascular disease in the 21st century. To this day, diet and medical therapy have proven only limited efficacy and bariatric surgery remains the last resort for many severely obese patients who wish to lose weight, modify their cardiovascular risk factors and ultimately modify their long-term prognosis. However, bariatric surgery remains associated with significant procedural morbidity and many patients are not eligible for such a surgery procedure as the risk-benefit ratio of bariatric surgery in severe obese patients with coronary artery disease is not yet well known.
- Recently, percutaneous left gastric artery embolization has been reported as a promising technique leading to a body weight loss that is equivalent to bariatric surgery.
- In the context of an endovascular procedure in obese patients, vascular access is a major concern. Transradial access (or radial artery approach) has been consistently associated with significant reductions in access-site related vascular complications and peri-procedural bleeding compared to the standard transfemoral access (or femoral artery approach). This is particularly evident in patients with severe obesity.
- Visceral arteries most often have an acute angulation with the aorta which makes them more easily cannulated from above (transradial access) compared to below (transfemoral access). Preliminary experience has shown that cannulation of the celiac artery is feasible from transfemoral and transradial access, the latter being associated with shorter procedural time and less contrast agent use. To date, several pilot studies have reported successful percutaneous embolization of the left gastric artery with biodegradable microspheres. This appears to be a promising technique to reduce weight in severely obese patients.
- Prior to launching a randomized trial, further study is warranted regarding the feasibility and safety aspects of transradial angiography of the celiac artery.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
RATIONALE:
- A significant proportion of patients referred to IUCPQ-UL catheterization laboratory are overweight (body mass index >25 kg/m²).
- Ongoing research and early clinical experience suggest that embolization of the left gastric artery could drastically reduce ghrelin levels and be associated with significant weight loss.
- In obese patients, catheterization using femoral artery access is associated with higher risks of vascular complications and peri-procedural bleeding compared to a radial artery approach.
- Given the anatomy (angle) of the celiac artery, selective catheterization of the celiac and left gastric arteries remains challenging, especially in obese patients.
- Before studying the effects of bariatric embolization, more data regarding the access of the left gastric artery is necessary.
HYPOTHESES:
- Transradial angiography of the celiac artery/left gastric artery is feasible and safe.
- Given the angulation of celiac artery, catheterization through a radial approach could be simpler.
- Selective angiography of the celiac artery and the left gastric artery can be performed in the setting of uncomplicated coronary angiography/percutaneous coronary intervention (PCI).
- Detailed anatomy of the celiac artery and its branches can be visualized by selective transradial angiography.
OBJECTIVES:
- The primary objective is to demonstrate the feasibility and safety of performing selective angiography of the celiac artery using a transradial approach in obese patients referred for diagnostic coronary angiography and/or PCI.
- The secondary objective is to observe anatomical variations of the celiac artery and the left gastric artery.
STUDY DESIGN:
> A prospective pilot study performed at Quebec Heart & Lung Institute (Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval; IUCPQ-UL).
Tipo de estudio
Intervencionista
Inscripción (Actual)
54
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Quebec
-
Quebec City, Quebec, Canadá, G1V 4G5
- Quebec Heart & Lung Institute (IUCPQ-UL)
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Patients undergoing coronary angiography with a BMI >30 kg/m² will be eligible.
Exclusion Criteria:
- Kidney disease defined by a glomerular filtration rate less than 60 ml/min/m² according to the Modification of Diet in Renal Disease (MDRD) formula;
- Previous gastric or bariatric surgery;
- Emergency coronary procedure.
Furthermore, the procedure will be cancelled if one of the following criteria are met during the coronary angiography:
- Contrast volume >250 ml;
- Radiation dose >180 Gy.cm² as assessed by the dose area product (DAP).
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Recruited patients
Transradial celiac artery angiography
|
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of successful selective angiographies
Periodo de tiempo: Baseline
|
The primary end-point will be the percentage of successful selective angiographies of the celiac artery.
|
Baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of complications of angiographies
Periodo de tiempo: Baseline
|
As catheterization and angiography of the celiac artery is an endovascular procedure, the incidence of vessel trauma (such as dissection or perforation) during the procedure will be assessed.
All cine films will be reviewed by a multidisciplinary team.
|
Baseline
|
|
Procedure duration
Periodo de tiempo: Baseline
|
Time (minutes) required to complete the angiography of the celiac artery
|
Baseline
|
|
Contrast volume
Periodo de tiempo: Baseline
|
Volume (mL) of contrast required to complete the angiography of the celiac artery
|
Baseline
|
|
Radiation exposure (duration)
Periodo de tiempo: Baseline
|
Fluoroscopy time (minutes) required to complete the angiography of the celiac artery
|
Baseline
|
|
Radiation exposure (dose)
Periodo de tiempo: Baseline
|
Dose area product (Gy·cm2) required to complete the angiography of the celiac artery
|
Baseline
|
|
Number of catheters
Periodo de tiempo: Baseline
|
The number of catheters required to complete the angiography of the celiac artery
|
Baseline
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Olivier F Bertrand, MD PhD, IUCPQ-UL and Laval University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
9 de febrero de 2018
Finalización primaria (Actual)
31 de mayo de 2019
Finalización del estudio (Actual)
30 de septiembre de 2019
Fechas de registro del estudio
Enviado por primera vez
30 de enero de 2018
Primero enviado que cumplió con los criterios de control de calidad
9 de febrero de 2018
Publicado por primera vez (Actual)
15 de febrero de 2018
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
26 de noviembre de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
25 de noviembre de 2019
Última verificación
1 de noviembre de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- EASY-AngioBar
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
INDECISO
Descripción del plan IPD
To be completed
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .